AstraZeneca’s rare disease unit posts positive Phase III data for new hypophosphatasia therapy

AstraZeneca ( (GB:AZN) ) has provided an announcement.

AstraZeneca reported positive top-line results from a global Phase III programme of efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy for hypophosphatasia, a rare inherited metabolic bone disease. The programme enrolled 196 paediatric, adolescent and adult patients across 22 countries, targeting both paediatric- and adult-onset forms and aiming to provide a lower-volume, less frequent dosing alternative to Strensiq.

In paediatric patients who were treatment-naive, the MULBERRY trial met its primary and key secondary endpoints, showing statistically significant and clinically meaningful improvements in bone health and physical function versus placebo. The CHESTNUT switch study showed that children moving from Strensiq to efzimfotase alfa maintained bone benefits with a favourable safety profile, reinforcing its potential as a more convenient successor therapy.

In adolescents and adults, the HICKORY trial did not reach statistical significance on its primary mobility endpoint due to strong placebo performance in adult-onset patients, but showed nominally significant gains in fatigue and clinically meaningful benefits in mobility, function and pain in prespecified subgroups with paediatric-onset disease. Extension data indicated continued improvements and meaningful efficacy after crossover from placebo, and across all three trials efzimfotase alfa was well tolerated, supporting a possible new standard of care and strengthening AstraZeneca’s positioning in rare metabolic bone disorders.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £165.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on AZN Stock

According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.

The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.

To see Spark’s full report on AZN stock, click here.

More about AstraZeneca

AstraZeneca, through its Alexion Rare Disease unit, operates in the biopharmaceutical industry with a focus on treatments for rare and severe disorders. The company develops enzyme replacement and targeted therapies, including Strensiq for hypophosphatasia, aiming to expand its presence in niche, high-value rare disease markets.

Average Trading Volume: 2,719,880

Technical Sentiment Signal: Buy

Current Market Cap: £221.8B

Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.